Code
3G0B2814
Duration
01 January 2014 → 31 December 2019
Funding
Research Foundation - Flanders (FWO)
Promotor
Research disciplines
-
Medical and health sciences
- Endocrinology and metabolic diseases
- Medical imaging and therapy
- Endocrinology and metabolic diseases
- Medical imaging and therapy
- Other paramedical sciences
- Biomarker discovery and evaluation
- Drug discovery and development
- Medicinal products
- Pharmaceutics
- Pharmacognosy and phytochemistry
- Pharmacology
- Pharmacotherapy
- Toxicology and toxinology
- Other pharmaceutical sciences
- Endocrinology and metabolic diseases
- Medical imaging and therapy
Keywords
perfluorocarbon nanoparticles
19F MRI
diabetes
Project description
Type 1 diabetes is an auto-immune disease in which the pancreatic beta-cells become selectively destroyed. In this project we aim to develop novel 19F MRI contrast agents which would enable in vivo kwantification of the developed immune responses. We will verify the selectivity and specificity of the developed contrast agents.